• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

每日低剂量施用生长激素促分泌素可刺激猪的生长激素脉冲式分泌,并提高血浆胰岛素样生长因子-1水平。

Daily low-dose administration of growth hormone secretagogue stimulates pulsatile growth hormone secretion and elevates plasma insulin-like growth factor-1 levels in pigs.

作者信息

Malmlöf K, Bauer M K, Johansen P B, Ankersen M, Veldhuis J D

机构信息

Pharmacological Research 3, Novo Nordisk A/S, Målov, Denmark.

出版信息

Endocrine. 2001 Dec;16(3):195-9. doi: 10.1385/ENDO:16:3:195.

DOI:10.1385/ENDO:16:3:195
PMID:11954663
Abstract

Repeated administration of growth hormone secretagogues (GHSs) has proven to be a delicate matter owing to development of tolerance. The aim of the present study was to define conditions during which the responsiveness to the orally active NN703 was maintained over several days. Growing pigs were fitted with stomach and vascular catheters, permitting unstressed intragastric administrations and blood sampling. NN703 or vehicle was administered once daily. When NN703 was given at a dose of 18 mg/kg, there was a massive acute increase in plasma growth hormone (GH) levels, but this was only seen on the first day of administration. A dose of 1.8 mg/kg did not cause a significant acute increase in plasma GH concentrations, whereas stimulation of pulsatile GH release was sustained over a 4-d period. During the first 7 h following injection of vehicle, the area under the curve of plasma GH was 1211+/-144 (microg/[L x 7 h]), but increased to 1770+/-269 and 1824+/-198 (microg/[L x 7 h]) on the first and fourth day of NN703 administration, respectively. Deconvolution analysis of the 7-h profiles revealed that the GH mass per burst as well as the GH burst amplitude were significantly (p < 0.001) increased during treatment with NN703, which led to an increase in pulsatile GH secretion rate (p < 0.001). Insulin-like growth factor-1 plasma concentrations increased steadily during NN703 administration (p < 0.01) and decreased after termination of treatment. The sustained increase in GH pulsatility observed with low-dose NN703 treatment suggests that development of tolerance to this GHS may be obviated by minimization of dose.

摘要

由于耐受性的产生,重复给予生长激素促分泌剂(GHSs)已被证明是一个棘手的问题。本研究的目的是确定在何种条件下,对口服活性药物NN703的反应性能够在数天内维持。给生长猪安装胃导管和血管导管,以便在无应激状态下进行胃内给药和采血。每天一次给予NN703或赋形剂。当以18 mg/kg的剂量给予NN703时,血浆生长激素(GH)水平出现大量急性升高,但仅在给药的第一天出现这种情况。1.8 mg/kg的剂量并未引起血浆GH浓度的显著急性升高,而脉冲式GH释放的刺激在4天的时间内持续存在。在注射赋形剂后的最初7小时内,血浆GH曲线下面积为1211±144(μg/[L×7 h]),但在给予NN703的第一天和第四天分别增加到1770±269和1824±198(μg/[L×7 h])。对7小时的曲线进行去卷积分析表明,在使用NN703治疗期间,每次脉冲的GH量以及GH脉冲幅度均显著增加(p<0.001),这导致脉冲式GH分泌率增加(p<0.001)。在给予NN703期间,胰岛素样生长因子-1血浆浓度稳步增加(p<0.01),并在治疗终止后下降。低剂量NN703治疗观察到的GH脉冲性持续增加表明,通过最小化剂量可能避免对这种GHS产生耐受性。

相似文献

1
Daily low-dose administration of growth hormone secretagogue stimulates pulsatile growth hormone secretion and elevates plasma insulin-like growth factor-1 levels in pigs.每日低剂量施用生长激素促分泌素可刺激猪的生长激素脉冲式分泌,并提高血浆胰岛素样生长因子-1水平。
Endocrine. 2001 Dec;16(3):195-9. doi: 10.1385/ENDO:16:3:195.
2
Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency.
Clin Endocrinol (Oxf). 2003 May;58(5):572-80. doi: 10.1046/j.1365-2265.2003.01754.x.
3
Pharmacological characterisation of a new oral GH secretagogue, NN703.新型口服生长激素促分泌素NN703的药理学特性
Eur J Endocrinol. 1999 Aug;141(2):180-9. doi: 10.1530/eje.0.1410180.
4
Growth hormone (GH) and insulin-like growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine.
Endocrinology. 1996 Nov;137(11):4851-6. doi: 10.1210/endo.137.11.8895356.
5
The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers.
Growth Horm IGF Res. 2000 Aug;10(4):193-8. doi: 10.1054/ghir.2000.0152.
6
The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects.健康男性受试者每日口服NN703治疗7天后的药代动力学、药效学、安全性和耐受性。
Growth Horm IGF Res. 2001 Feb;11(1):41-8. doi: 10.1054/ghir.2000.0188.
7
Do growth hormone-releasing peptides act as ghrelin secretagogues?生长激素释放肽是否作为胃饥饿素促分泌剂起作用?
Endocrine. 2001 Feb;14(1):133-5. doi: 10.1385/ENDO:14:1:133.
8
Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.通过连续24小时输注生长激素释放肽对女性生长激素(GH)轴进行三方神经内分泌激活:脉冲式、熵性和昼夜机制。
J Clin Endocrinol Metab. 1999 Jun;84(6):2140-50. doi: 10.1210/jcem.84.6.5687.
9
An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women.生长激素(GH)分泌的脉动模式中特定幅度的差异是男性和绝经前女性平均GH浓度存在性别差异的基础。
J Clin Endocrinol Metab. 1996 Jul;81(7):2460-7. doi: 10.1210/jcem.81.7.8675561.
10
Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.通过一种新型、强效且选择性的生长激素(GH)受体拮抗剂培维索孟(B2036-聚乙二醇)降低血浆总胰岛素样生长因子I浓度,可增加健康女性和男性中GH分泌脉冲的幅度,并提高基础/非脉冲性GH释放。
J Clin Endocrinol Metab. 2001 Jul;86(7):3304-10. doi: 10.1210/jcem.86.7.7656.

本文引用的文献

1
A role for ghrelin in the central regulation of feeding.胃饥饿素在进食的中枢调节中的作用。
Nature. 2001 Jan 11;409(6817):194-8. doi: 10.1038/35051587.
2
Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats.胃饥饿素对自由活动大鼠的生长激素分泌有显著的刺激作用。
Eur J Endocrinol. 2000 Nov;143(5):R7-9. doi: 10.1530/eje.0.143r007.
3
The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers.
Growth Horm IGF Res. 2000 Aug;10(4):193-8. doi: 10.1054/ghir.2000.0152.
4
Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats.一种新型酰化肽——胃饥饿素对大鼠生长激素释放的中枢作用。
Biochem Biophys Res Commun. 2000 Aug 28;275(2):477-80. doi: 10.1006/bbrc.2000.3342.
5
Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal.以酰肼作为C端的源自NN703的生长激素促分泌素
Eur J Med Chem. 2000 May;35(5):487-97. doi: 10.1016/s0223-5234(00)00146-x.
6
Growth hormone secretagogue actions on the pituitary gland: multiple receptors for multiple ligands?
Clin Exp Pharmacol Physiol. 2000 May-Jun;27(5-6):323-9. doi: 10.1046/j.1440-1681.2000.03258.x.
7
High plasma growth hormone (GH) levels inhibit expression of GH secretagogue receptor messenger ribonucleic acid levels in the rat pituitary.高血浆生长激素(GH)水平会抑制大鼠垂体中生长激素促分泌素受体信使核糖核酸水平的表达。
Endocrinology. 2000 Jun;141(6):2084-9. doi: 10.1210/endo.141.6.7503.
8
Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats.
Growth Horm IGF Res. 1999 Dec;9(6):445-50. doi: 10.1054/ghir.1999.0128.
9
Ghrelin is a growth-hormone-releasing acylated peptide from stomach.胃饥饿素是一种由胃产生的可释放生长激素的酰化肽。
Nature. 1999 Dec 9;402(6762):656-60. doi: 10.1038/45230.
10
Growth hormone releasing substances: types and their receptors.生长激素释放物质:类型及其受体。
Horm Res. 1999;51 Suppl 3:1-8. doi: 10.1159/000044375.